Tranzactioneaza Apellis Pharmaceuticals (US.APLS) - 34.13 USD (%) Tranzactioneaza

1D
1W
1M
3M
6M
1Y
5Y
Max

Indici

Bid 32.000 USD
Ask 35.100 USD
Minim 34.020 USD
Maxim 34.630 USD
Pret referinta 34.130
Volum -
Volum ultima zi 1
Max 52 sapt 73.800 USD
Min 52 sapt 24.340 USD

Descriere companie

Apellis Pharmaceuticals, Inc. (www.apellis.com) is a clinical-stage biopharmaceutical company that is focused on developing novel therapeutic compounds to treat disease through the inhibition of the complement system. The Company is developing pegcetacoplan with Sobi for systemic administration in several indications, including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, cold agglutinin disease, and hematopoietic stem cell transplantation thrombotic microangiopathy. The Company's advanced clinical programs targeting component 3 with Phase III clinical trials of its lead product candidate, pegcetacoplan, in multiple indications. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for ophthalmological administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.

Informatii companie

Nume

Apellis Pharmaceuticals, Inc.